Prevalence and Genetic Alternation of Autoimmune Polyglandular Syndrome Type II in Taiwan
1 other identifier
observational
650
1 country
1
Brief Summary
Autoimmune polyendocrine syndrome (APS) is an autoimmune disease involving at least two endocrine organ. It is classified into type I and type II diseases. Among them, APS type II is more common. It is diagnosed when two of the three following diseases are diagnosed in the same patient, including type 1 diabetes mellitus, autoimmune thyroid disease, and primary adrenal insufficiency. In this study, we will observe the epidemiology, clinical characteristics, and genetic variants of APS II in Taiwan.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2022
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2022
CompletedFirst Submitted
Initial submission to the registry
October 10, 2022
CompletedFirst Posted
Study publicly available on registry
October 13, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
October 13, 2022
October 1, 2022
5 years
October 10, 2022
October 10, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Rates of endocrine organs involved
We will observe the rate of each endocrine organ involved, including adrenal gland, thyroid, and pancreas
2022/1/1 ~ 2026/12/31
Study Arms (1)
Autoimmune polyendocrine syndrome type II
patients with autoimmune polyendocrine syndrome type II
Interventions
Eligibility Criteria
We study patients with autoimmune polyendocrine syndrome type II
You may qualify if:
- Patients visited NTUH during 2006-2021, and had at least two of the three diseases: type 1 DM, primary adrenal insufficiency, and autoimmune thyroid disease.
You may not qualify if:
- Patients aged less than 20 years old
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National Taiwan University Hospital
Taipei, 100, Taiwan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Shyang-Rong Shih, MD, PhD
National Taiwan University Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 10, 2022
First Posted
October 13, 2022
Study Start
January 1, 2022
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2026
Last Updated
October 13, 2022
Record last verified: 2022-10
Data Sharing
- IPD Sharing
- Will not share